Radovich Peter 4

What Happened Peter Radovich, President and Chief Operating Officer of Mirum Pharmaceuticals (MIRM), was granted three equity awards on January 28, 2026 totaling 75,900 derivative units (25,120 + 16,280 + 34,500). Each award was reported as acquired at $0.00 per unit (these are equity grants, not open‑market purchases or sales). The awards are restricted stock units (RSUs) and performance RSUs (PSUs) that convert to common shares upon vesting; no cash changed hands at grant.

Key Details

• Transaction date: January 28, 2026; Form 4 filed January 30, 2026 (timely filing).
• Consideration: $0.00 per unit (derivative awards, not purchases).
• Total units granted: 75,900 RSUs/PSUs.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting/footnotes:
  • One award vests 25% one year after Jan 28, 2026, then monthly over the next 36 months.
  • One award vests 1/3 on each anniversary of Jan 28, 2026 (fully vested after 3 years).
  • A PSU award (granted Jan 23, 2024) had performance criteria met on Jan 28, 2026; that award vests 2/3 on Mar 15, 2026 and 1/3 on Mar 15, 2027.
• These entries are coded as "A" (award/grant) and are derivative (convert to shares upon vesting).

Context These grants are executive compensation—common for senior management—and represent future contingent rights to Mirum common stock if vesting conditions are met. Because no shares were bought or sold and no cash was exchanged at grant, the awards do not indicate an immediate market purchase or sale by the insider. The filing appears timely (filed two days after the grant date).